Jaypirca

pirtobrutinib

Approval

ApplicationNDA 216059
Approval dateJan 27, 2023
Approval year2023
SponsorLoxo Oncol

FDA-approved use

To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Jaypirca: